A5033497592- Lung Cancer Treatments and Mutations
- Ovarian cancer diagnosis and treatment
- Advanced Breast Cancer Therapies
- Gastric Cancer Management and Outcomes
- Gastrointestinal Tumor Research and Treatment
- Colorectal Cancer Treatments and Studies
- Reproductive Biology and Fertility
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Sarcoma Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer, Lipids, and Metabolism
- Pneumocystis jirovecii pneumonia detection and treatment
- HIV/AIDS drug development and treatment
- Lung Cancer Diagnosis and Treatment
- Traumatic Ocular and Foreign Body Injuries
- Nanoparticle-Based Drug Delivery
- Cardiovascular and Diving-Related Complications
- Bone health and treatments
- Cancer-related Molecular Pathways
- Neurofibromatosis and Schwannoma Cases
- Antibiotics Pharmacokinetics and Efficacy
- PARP inhibition in cancer therapy
- Peptidase Inhibition and Analysis
Pfizer (China)
2015-2021
Aims The objective of this study was to evaluate the effects a strong cytochrome P450 family (CYP) 3A4 inhibitor (itraconazole) and inducer (carbamazepine) on pharmacokinetics safety nirmatrelvir/ritonavir. Methods Pharmacokinetics were measured in two phase 1, open‐label, fixed‐sequence studies healthy adults. During Period oral nirmatrelvir/ritonavir 300 mg/100 mg twice daily administered alone; during 2, it with itraconazole or carbamazepine. Nirmatrelvir/ritonavir as repeated doses one...
This phase I/II study was conducted to determine the maximum recommended dose of pemetrexed when given in combination with a fixed cisplatin, and efficacy, toxicity association 5,10-methylenetetrahydrofolate reductase (MTHFR) variants this pemetrexed--cisplatin combination, patients unresectable, advanced gastric carcinoma. Patients 18–70 years age, stage IV disease or post-surgery recurrence, no earlier palliative chemotherapy, 0 1 Eastern Cooperative Oncology Group performance status, were...
<h3>Introduction</h3> In the JAVELIN Ovarian 100 trial (NCT02718417), avelumab (anti–PD-L1) in combination with chemotherapy or as maintenance did not improve progression-free survival (PFS) vs followed by observation treatment-naive patients epithelial ovarian cancer (EOC; hazard ratios [95% CI] were 1.14 [0.832, 1.565] and 1.43 [1.051, 1.946], respectively). The was terminated when prespecified futility boundaries crossed at interim analysis, study treatment subsequently discontinued. Here...
Abstract Introduction Sunitinib is approved in China for treatment of gastrointestinal stromal tumors (GIST), after disease progression on, or intolerance to, imatinib. However, available data from prospective clinical trials on its efficacy and safety Chinese patients limited. Our objective to determine the sunitinib with imatinib-resistant/intolerant GIST. Methods An open-label, single-arm, multicenter, phase IV study was performed administered orally 6-week cycles 4 weeks on-treatment (50...
e15208 Background: The effectiveness and safety of sunitinib in GIST were largely established Western patients. We report the first prospective study for this indication China. purpose single-arm reported here was to assess use Chinese patients with imatinib (IM)-resistant/-intolerant GIST. Methods: Patients failed line IM at multiple centers China received oral 50 mg/day on approved 4-weeks-on-2-weeks-off schedule. primary endpoint progression-free survival (PFS). Tumor measurements...
e17546 Background: CD47, an overexpressed factor correlated with poor clinical characteristics and prognosis in OC, is innate immune checkpoint that binds signal regulatory protein alpha (SIRPα) delivers a to suppress macrophage phagocytosis. Maplirpacept (PF-07901801) fusion consisting of the CD47-binding domain human SIRPα linked Fc region IgG4, enhancing phagocytosis by blocking CD47. Blockade both alone combined doxorubicin, has shown anti-tumor activity vitro vivo xenograft animal...
7591 Background: Asian, n/smkr NSCLC pts show more favorable clinical course and improved outcomes when treated with EGFR-TKIs or chemo, particularly in presence of EGFR mutations (mut). In unknown mut status pts, optimal selection/integration both modalities is unclear. This trial compared first-line sequential (seq) txt PC followed by either G P. Methods: n/smkr, chemonaive, stage IIIB/IV ECOG PS ≤1 status, were randomized to Arm A (4 cycles: P[500 mg/m2] + C[75 q3 wks [250 mg/d]) B...
A defibrination syndrome developed in two men (aged 51, and 29 years old) within hours of having been bitten by vipers Echis carinatus Agkistrodon halys, respectively. In both the was characterized afibrinogenemia with prolongation thrombin time, presence fibrin monomers split products fibrinogen. Haemorrhagic signs included oral mucosa bleeding macrohematuria. Specific serum administered 9 16 hours, respectively, after bite achieved normalization all clotting values 48 hours.
Abstract Background The cyclin-dependent kinase (CDK) 4/6 inhibitor PAL is approved for treatment of estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) ABC in combination with endocrine therapy. This ongoing, phase 1, open-label, single-arm study (NCT02499146) evaluating the pharmacokinetics, safety, and efficacy PAL+L as first-line ER+/HER2– Chinese women. longitudinal alterations multiple pharmacodynamic biomarkers related to mechanism action cell...